{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T18:12:49Z","timestamp":1789495969764,"version":"build-2803163510"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T00:00:00Z","timestamp":1752192000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T00:00:00Z","timestamp":1752192000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s00198-025-07602-1","type":"journal-article","created":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T17:53:34Z","timestamp":1752256414000},"page":"1391-1403","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Comparison of bone mineral density changes between denosumab and bisphosphonates in tenofovir-exposed chronic hepatitis B patients with osteoporosis"],"prefix":"10.1007","volume":"36","author":[{"given":"Yunmi","family":"Ko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byeong Geun","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyunjae","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youngsu","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeayeon","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min Kyung","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun Bin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su Jong","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong Hyun","family":"Sinn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoon Jun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung-Hwan","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung Shin","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moon Haeng","family":"Hur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0315-2080","authenticated-orcid":false,"given":"Jeong-Hoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,11]]},"reference":[{"key":"7602_CR1","unstructured":"World Health Organization (2021) Global progress report on HIV, viral hepatitis and sexually transmitted infections. Accountability for the global health sector strategies 2016\u20132021: actions for impact. WHO, Geneva. https:\/\/www.who.int\/publications\/i\/item\/9789240027077"},{"issue":"9865","key":"7602_CR2","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/S0140-6736(12)61425-1","volume":"381","author":"P Marcellin","year":"2013","unstructured":"Marcellin P, Gane E, Buti M et al (2013) Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 381(9865):468\u2013475","journal-title":"Lancet"},{"issue":"3","key":"7602_CR3","doi-asserted-by":"publisher","first-page":"605","DOI":"10.3350\/cmh.2022.0342","volume":"29","author":"C-L Lin","year":"2023","unstructured":"Lin C-L, Kao J-H (2023) Development of hepatocellular carcinoma in treated and untreated patients with chronic hepatitis B virus infection. Clin Mol Hepatol 29(3):605\u2013622","journal-title":"Clin Mol Hepatol"},{"issue":"2","key":"7602_CR4","doi-asserted-by":"publisher","first-page":"276","DOI":"10.3350\/cmh.2022.0084","volume":"28","author":"JW Jang","year":"2022","unstructured":"Jang JW, Park JY, Kwon JH et al (2022) KASL clinical practice guidelines for management of chronic hepatitis B. Clin Mol Hepatol 28(2):276\u2013331","journal-title":"Clin Mol Hepatol"},{"issue":"1","key":"7602_CR5","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3350\/cmh.2023.0328","volume":"30","author":"H Hong","year":"2023","unstructured":"Hong H, Choi W-M, Lee D et al (2023) Cardiovascular risk in chronic hepatitis B patients treated with tenofovir disoproxil fumarate or tenofovir alafenamide. Clin Mol Hepatol 30(1):49\u201363","journal-title":"Clin Mol Hepatol"},{"issue":"4","key":"7602_CR6","doi-asserted-by":"publisher","first-page":"583","DOI":"10.3350\/cmh.2022.0294","volume":"28","author":"Korean Liver Cancer Association (KLCA) and National Cancer Center (NCC) Korea","year":"2022","unstructured":"Korean Liver Cancer Association (KLCA) and National Cancer Center (NCC) Korea (2022) 2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma. Clin Mol Hepatol. 28(4):583\u2013705","journal-title":"Clin Mol Hepatol"},{"issue":"8","key":"7602_CR7","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1111\/j.1742-1241.2008.01817.x","volume":"62","author":"A Pozniak","year":"2008","unstructured":"Pozniak A (2008) Tenofovir: what have over 1 million years of patient experience taught us? Int J Clin Pract 62(8):1285\u20131293","journal-title":"Int J Clin Pract"},{"issue":"6","key":"7602_CR8","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1053\/ajkd.2002.36924","volume":"40","author":"D Verhelst","year":"2002","unstructured":"Verhelst D, Monge M, Meynard J-L et al (2002) Fanconi syndrome and renal failure induced by tenofovir: a first case report. Am J Kidney Dis 40(6):1331\u20131333","journal-title":"Am J Kidney Dis"},{"issue":"9","key":"7602_CR9","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1007\/s40264-018-0665-z","volume":"41","author":"A Komatsu","year":"2018","unstructured":"Komatsu A, Ikeda A, Kikuchi A, Minami C, Tan M, Matsushita S (2018) Osteoporosis-related fractures in HIV-infected patients receiving long-term tenofovir disoproxil fumarate: an observational cohort study. Drug Saf 41(9):843\u2013848","journal-title":"Drug Saf"},{"issue":"3","key":"7602_CR10","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1097\/COH.0000000000000248","volume":"11","author":"PM Grant","year":"2016","unstructured":"Grant PM, Cotter AG (2016) Tenofovir and bone health. Curr Opin HIV AIDS 11(3):326\u2013332","journal-title":"Curr Opin HIV AIDS"},{"issue":"3","key":"7602_CR11","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/S2468-1253(16)30107-8","volume":"1","author":"M Buti","year":"2016","unstructured":"Buti M, Gane E, Seto WK et al (2016) Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol 1(3):196\u2013206","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"3","key":"7602_CR12","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/S2468-1253(16)30024-3","volume":"1","author":"HL Chan","year":"2016","unstructured":"Chan HL, Fung S, Seto WK et al (2016) Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol 1(3):185\u2013195","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"7602_CR13","doi-asserted-by":"publisher","first-page":"411","DOI":"10.3350\/cmh.2020.0049","volume":"26","author":"HJ Yim","year":"2020","unstructured":"Yim HJ, Kim JH, Park JY et al (2020) Comparison of clinical practice guidelines for the management of chronic hepatitis B: When to start, when to change, and when to stop. Clin Mol Hepatol 26(4):411\u2013429","journal-title":"Clin Mol Hepatol"},{"issue":"4","key":"7602_CR14","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.jhep.2017.11.039","volume":"68","author":"K Agarwal","year":"2018","unstructured":"Agarwal K, Brunetto M, Seto WK et al (2018) 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. J Hepatol 68(4):672\u2013681","journal-title":"J Hepatol"},{"issue":"1","key":"7602_CR15","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.bbrc.2010.02.080","volume":"394","author":"IF Grigsby","year":"2010","unstructured":"Grigsby IF, Pham L, Mansky LM, Gopalakrishnan R, Carlson AE, Mansky KC (2010) Tenofovir treatment of primary osteoblasts alters gene expression profiles: implications for bone mineral density loss. Biochem Biophys Res Commun 394(1):48\u201353","journal-title":"Biochem Biophys Res Commun"},{"key":"7602_CR16","first-page":"41","volume":"6","author":"IF Grigsby","year":"2010","unstructured":"Grigsby IF, Pham L, Mansky LM, Gopalakrishnan R, Mansky KC (2010) Tenofovir-associated bone density loss. Ther Clin Risk Manag 6:41\u201347","journal-title":"Ther Clin Risk Manag"},{"issue":"3","key":"7602_CR17","doi-asserted-by":"publisher","first-page":"486","DOI":"10.14309\/ajg.0000000000002468","volume":"119","author":"HLY Chan","year":"2024","unstructured":"Chan HLY, Buti M, Lim YS et al (2024) Long-term treatment with tenofovir alafenamide for chronic hepatitis B results in high rates of viral suppression and favorable renal and bone safety. Am J Gastroenterol 119(3):486\u2013496","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"7602_CR18","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1210\/clinem\/dgaa048","volume":"105","author":"D Shoback","year":"2020","unstructured":"Shoback D, Rosen CJ, Black DM, Cheung AM, Murad MH, Eastell R (2020) Pharmacological management of osteoporosis in postmenopausal women: an endocrine society guideline update. J Clin Endocrinol Metab 105(3):587\u2013594","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"7602_CR19","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1111\/ijcp.12022","volume":"66","author":"DA Hanley","year":"2012","unstructured":"Hanley DA, Adachi JD, Bell A, Brown V (2012) Denosumab: mechanism of action and clinical outcomes. Int J Clin Pract 66(12):1139\u20131146","journal-title":"Int J Clin Pract"},{"issue":"4","key":"7602_CR20","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.bone.2010.11.020","volume":"48","author":"R Baron","year":"2011","unstructured":"Baron R, Ferrari S, Russell RGG (2011) Denosumab and bisphosphonates: different mechanisms of action and effects. Bone 48(4):677\u2013692","journal-title":"Bone"},{"issue":"2","key":"7602_CR21","first-page":"92","volume":"43","author":"KN Tu","year":"2018","unstructured":"Tu KN, Lie JD, Wan CKV et al (2018) Osteoporosis: a review of treatment options. Pharm Ther 43(2):92\u2013104","journal-title":"Pharm Ther"},{"issue":"7","key":"7602_CR22","doi-asserted-by":"publisher","first-page":"364","DOI":"10.11622\/smedj.2019028","volume":"60","author":"T Chandran","year":"2019","unstructured":"Chandran T, Venkatachalam I (2019) Efficacy and safety of denosumab compared to bisphosphonates in improving bone strength in postmenopausal osteoporosis: a systematic review. Singapore Med J 60(7):364\u2013378","journal-title":"Singapore Med J"},{"issue":"2","key":"7602_CR23","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1002\/hep.30904","volume":"71","author":"Y Arase","year":"2020","unstructured":"Arase Y, Tsuruya K, Hirose S et al (2020) Efficacy and safety of 3-Year denosumab therapy for osteoporosis in patients with autoimmune liver diseases. Hepatology 71(2):757\u2013759","journal-title":"Hepatology"},{"issue":"1","key":"7602_CR24","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s13256-019-2018-7","volume":"13","author":"T Kunii","year":"2019","unstructured":"Kunii T, Iijima T, Jojima T et al (2019) Denosumab improves clinical manifestations of hypophosphatemic osteomalacia by adefovir-induced Fanconi syndrome: a case report. J Med Case Rep 13(1):99","journal-title":"J Med Case Rep"},{"key":"7602_CR25","volume-title":"Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO technical report series","author":"World Health Organization","year":"1994","unstructured":"World Health Organization (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO technical report series. WHO, Geneva"},{"issue":"5","key":"7602_CR26","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1210\/jc.2018-02236","volume":"104","author":"H Lyu","year":"2019","unstructured":"Lyu H, Jundi B, Xu C et al (2019) Comparison of denosumab and bisphosphonates in patients with osteoporosis: a meta-analysis of randomized controlled trials. J Clin Endocrinol Metab 104(5):1753\u20131765","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"7602_CR27","first-page":"213","volume":"27","author":"H Tsurukami","year":"2017","unstructured":"Tsurukami H (2017) Acute phase reaction following bisphosphonates. Clin Calcium 27(2):213\u2013223","journal-title":"Clin Calcium"},{"issue":"1","key":"7602_CR28","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13722-024-00464-8","volume":"19","author":"PP Acharya","year":"2024","unstructured":"Acharya PP, Joseph C (2024) An acute phase reaction from zoledronate mimicking symptoms seen in opioid withdrawal: a case report. Addict Sci Clin Pract 19(1):34","journal-title":"Addict Sci Clin Pract"},{"issue":"1","key":"7602_CR29","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3851\/IMP3346","volume":"25","author":"B Baranek","year":"2020","unstructured":"Baranek B, Wang S, Cheung AM, Mishra S, Tan DH (2020) The effect of tenofovir disoproxil fumarate on bone mineral density: a systematic review and meta-analysis. Antivir Ther 25(1):21\u201332","journal-title":"Antivir Ther"},{"issue":"3","key":"7602_CR30","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1093\/infdis\/jiu471","volume":"211","author":"US Gill","year":"2015","unstructured":"Gill US, Zissimopoulos A, Al-Shamma S et al (2015) Assessment of bone mineral density in tenofovir-treated patients with chronic hepatitis B: can the fracture risk assessment tool identify those at greatest risk? J Infect Dis 211(3):374\u2013382","journal-title":"J Infect Dis"},{"issue":"2","key":"7602_CR31","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.cegh.2019.10.001","volume":"8","author":"E Hajiani","year":"2020","unstructured":"Hajiani E, Parsi A, Seyedian SS, Rajaei E, Jolodarian P (2020) Comparing the frequency of osteoporosis and osteopenia in chronic hepatitis B patients with and without Tenofovir treatment. Clin Epidemiol Glob Health 8(2):428\u2013431","journal-title":"Clin Epidemiol Glob Health"},{"issue":"5","key":"7602_CR32","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1002\/jbmr.3665","volume":"34","author":"FM Conesa-Buend\u00eda","year":"2019","unstructured":"Conesa-Buend\u00eda FM, Llamas-Granda P, Larra\u00f1aga-Vera A et al (2019) Tenofovir causes bone loss via decreased bone formation and increased bone resorption, which can be counteracted by dipyridamole in mice. J Bone Miner Res 34(5):923\u2013938","journal-title":"J Bone Miner Res"},{"issue":"50","key":"7602_CR33","doi-asserted-by":"publisher","first-page":"e2276","DOI":"10.1097\/MD.0000000000002276","volume":"94","author":"CH Chen","year":"2015","unstructured":"Chen CH, Lin CL, Kao CH (2015) Association between chronic hepatitis B virus infection and risk of osteoporosis: a nationwide population-based study. Medicine (Baltimore) 94(50):e2276","journal-title":"Medicine (Baltimore)"},{"issue":"5","key":"7602_CR34","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.3390\/ijms19051308","volume":"19","author":"A Adamek","year":"2018","unstructured":"Adamek A, Kasprzak A (2018) Insulin-Like Growth Factor (IGF) system in liver diseases. Int J Mol Sci 19(5):1308","journal-title":"Int J Mol Sci"},{"issue":"12","key":"7602_CR35","first-page":"4257","volume":"83","author":"JA Langlois","year":"1998","unstructured":"Langlois JA, Rosen CJ, Visser M et al (1998) Association between insulin-like growth factor I and bone mineral density in older women and men: the framingham heart study1. J Clin Endocrinol Metab 83(12):4257\u20134262","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"7602_CR36","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/S8756-3282(98)00186-0","volume":"24","author":"T Seck","year":"1999","unstructured":"Seck T, Bretz A, Krempien R, Krempien B, Ziegler R, Pfeilschifter J (1999) Age-related changes in insulin-like growth factor I and II in human femoral cortical bone: lack of correlation with bone mass. Bone 24(4):387\u2013393","journal-title":"Bone"},{"issue":"4","key":"7602_CR37","doi-asserted-by":"publisher","first-page":"233","DOI":"10.14740\/jocmr2761w","volume":"9","author":"RG De La Garza","year":"2017","unstructured":"De La Garza RG, Morales-Garza LA, Martin-Estal I, Castilla-Cortazar I (2017) Insulin-like growth factor-1 deficiency and cirrhosis establishment. J Clin Med Res 9(4):233\u2013247","journal-title":"J Clin Med Res"},{"issue":"17","key":"7602_CR38","doi-asserted-by":"publisher","first-page":"4270","DOI":"10.3390\/ijms20174270","volume":"20","author":"HM Jeong","year":"2019","unstructured":"Jeong HM, Kim DJ (2019) Bone diseases in patients with chronic liver disease. Int J Mol Sci 20(17):4270","journal-title":"Int J Mol Sci"},{"issue":"1","key":"7602_CR39","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1186\/1479-5876-11-271","volume":"11","author":"L Guerra-Men\u00e9ndez","year":"2013","unstructured":"Guerra-Men\u00e9ndez L, S\u00e1daba MC, Puche JE et al (2013) IGF-I increases markers of osteoblastic activity and reduces bone resorption via osteoprotegerin and RANK-ligand. J Transl Med 11(1):271","journal-title":"J Transl Med"},{"issue":"2","key":"7602_CR40","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/emm.2002.21","volume":"34","author":"YH Kim","year":"2002","unstructured":"Kim YH, Kim G-S, Baek J-H (2002) Inhibitory action of bisphosphonates on bone resorption does not involve the regulation of RANKL and OPG expression. Exp Mol Med 34(2):145\u2013151","journal-title":"Exp Mol Med"},{"issue":"8","key":"7602_CR41","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"Cummings SR, Martin JS, McClung MR et al (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361(8):756\u2013765","journal-title":"N Engl J Med"},{"issue":"15","key":"7602_CR42","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","volume":"377","author":"KG Saag","year":"2017","unstructured":"Saag KG, Petersen J, Brandi ML et al (2017) Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med 377(15):1417\u20131427","journal-title":"N Engl J Med"},{"issue":"2","key":"7602_CR43","doi-asserted-by":"publisher","first-page":"448","DOI":"10.3390\/idr13020044","volume":"13","author":"M Rao","year":"2021","unstructured":"Rao M, Dadey L, Glowa T, Veldkamp P (2021) Fanconi syndrome leading to hypophosphatemic osteomalacia related to tenofovir use. Infect Dis Rep 13(2):448\u2013453","journal-title":"Infect Dis Rep"},{"issue":"4","key":"7602_CR44","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1093\/ckj\/sfv041","volume":"8","author":"S Waheed","year":"2015","unstructured":"Waheed S, Attia D, Estrella MM et al (2015) Proximal tubular dysfunction and kidney injury associated with tenofovir in HIV patients: a case series. Clin Kidney J 8(4):420\u2013425","journal-title":"Clin Kidney J"},{"issue":"2","key":"7602_CR45","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s00198-010-1501-1","volume":"22","author":"S Vasikaran","year":"2011","unstructured":"Vasikaran S, Eastell R, Bruy\u00e8re O et al (2011) Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int 22(2):391\u2013420","journal-title":"Osteoporos Int"},{"key":"7602_CR46","first-page":"10","volume":"8","author":"JC Ahn","year":"2022","unstructured":"Ahn JC, Lee Y-T, Agopian VG et al (2022) Hepatocellular carcinoma surveillance: current practice and future directions. Hepatoma Res 8:10","journal-title":"Hepatoma Res"}],"updated-by":[{"DOI":"10.1007\/s00198-025-07649-0","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T00:00:00Z","timestamp":1755820800000}}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-025-07602-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-025-07602-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-025-07602-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T08:06:39Z","timestamp":1757232399000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-025-07602-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,11]]},"references-count":46,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["7602"],"URL":"https:\/\/doi.org\/10.1007\/s00198-025-07602-1","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s00198-025-07649-0","asserted-by":"object"}]},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,11]]},"assertion":[{"value":"26 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Reference #6 contains an incorrect author attribution. The author name currently appears incorrectly as: Korea KLCAKaNCCN","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The correct author attribution should be: Korean Liver Cancer Association (KLCA) and National Cancer Center (NCC) Korea","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original article has been corrected.","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2025","order":10,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":11,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":12,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00198-025-07649-0","URL":"https:\/\/doi.org\/10.1007\/s00198-025-07649-0","order":13,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"For this type of study formal consent is not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Yunmi Ko: Nothing to declare; Byeong Geun Song: Nothing to declare; Hyunjae Shin: Nothing to declare; Youngsu Park: Nothing to declare; Jeayeon Park: Nothing to declare; Min Kyung Park: Nothing to declare; Yun Bin Lee: Receives research grants from Samjin Pharmaceuticals and Yuhan Pharmaceuticals; Su Jong Yu: Receives research grants from Yuhan Pharmaceuticals and Daewoong Pharmaceuticals; Dong Hyun Sinn: Nothing to declare; Yoon Jun Kim: Receives research grants from Roche, JW Creagene, Bukwang Pharmaceutical, Handok Pharmaceuticals, Hanmi, Bristol Myers Squibb, Yuhan Pharmaceuticals, and PharmaKing, and lecture fees from Bayer, Gilead Sciences, MSD, Yuhan Pharmaceuticals, Samil Pharmaceuticals, CJ Pharmaceuticals, Bukwang Pharmaceutical, and Handok Pharmaceuticals; Jung-Hwan Yoon: Receives research grants from Bayer, Daewoong Pharmaceutical, and Bukwang Pharmaceutical; Seung-Shin Park: Nothing to declare; Moon Haeng Hur: Nothing to declare; Jeong-Hoon Lee: Receives research grants from Yuhan Pharmaceuticals and GreenCross Cell, lecture fees from GreenCross Cell, Daewoong Pharmaceuticals, and Gilead Korea.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}